RNAImmune Raises $10 Million for mRNA Products and COVID-19 Vaccine
April 22, 2021 at 05:48 AM EDT
RNAImmune, a spinout from Sirnaomics, raised $10 million in seed capital to develop mRNA therapeutics and vaccines. Sirnaomics, a Maryland-Guangzhou biopharma, discovers and develops RNAi therapeutics for cancer and fibrotic disease indications. Founded in 2020, RNAimmune is in the IND enabling stage for its lead candidate, a COVID-19 mRNA vaccine with plans to file an IND with the US FDA before the end of 2021. The seed round was led by Smooth River of Las Vegas and Hong Kong Hongrun. More details.... Share this with colleagues: // //